Related Experiment Video

Updated: May 25, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination

Henry A Punzi1

  • 1Trinity Hypertension and Metabolic Research Institute, Punzi Medical Center, Carrollton, TX, USA; Department of Family and Community Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

Integrated Blood Pressure Control
|January 19, 2012
PubMed

Insights

Uncontrolled high blood pressure (hypertension) affects many Americans. Combination therapy with olmesartan medoxomil and hydrochlorothiazide offers an effective treatment strategy for managing hypertension.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Hypertension impacts nearly one-third of US adults, with half of treated patients not reaching target blood pressure (BP) goals.
  • Uncontrolled BP elevates risks for cardiovascular events and end-organ damage.
  • Antihypertensive monotherapy often proves insufficient, necessitating more aggressive treatment strategies.

Purpose of the Study:

  • To review the benefits of combination therapy using olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ) for hypertension management.
  • To examine the pharmacokinetic properties of OM and efficacy of OM + HCTZ.
  • To provide a rationale for selecting HCTZ over chlorthalidone in combination therapy.

Main Methods:

  • Review of pharmacokinetic properties of olmesartan medoxomil.
  • Analysis of efficacy studies comparing OM + HCTZ combination therapy with other antihypertensive regimens.
  • Discussion of clinical concerns and trends in diuretic use, specifically HCTZ versus chlorthalidone.

Main Results:

  • Combination therapy targets different mechanisms of action, potentially improving tolerability and BP control.
  • Evidence supports the efficacy of OM + HCTZ in achieving BP goals.
  • Pharmacokinetic differences and clinical considerations inform the choice between HCTZ and chlorthalidone.

Conclusions:

  • Antihypertensive combination therapy, particularly with renin-angiotensin system inhibitors like OM, is crucial for achieving BP control.
  • The combination of OM and HCTZ presents a valuable therapeutic option for managing hypertension.
  • Understanding pharmacokinetic and clinical factors is essential for optimizing antihypertensive treatment strategies.

Keywords:
HCTZantihypertensivesblood pressurecombination therapy

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...